Efficacy and safety of modified tetracycline dosing in a quadruple therapy for Helicobacter pylori: A retrospective single center study

Table 4 Drug adverse events in different treatment groups (n/N)

Group	500 mg b.i.d.	750 mg b.i.d.	500 mg t.i.d.	All	P
Taste distortion	2	6	8	16	0.060
Nausea	2	6	4	12	0.190
Abdominal pain	1	2	0	3	0.320
Vomiting	0	1	0	1	0.310
Bloating	3	0	1	4	0.290
Diarrhea	4	2	1	7	0.570
Dizziness	1	2	1	4	0.670
Skin rash	3	4	3	10	0.740
Fatigue	1	4	1	6	0.140
Fever	4	6	8	18	0.250
Constipation	1	1	0	2	0.630
Decreased appetite	0	3	7	10	0.009
Chills	0	1	0	1	0.310
Melena	0	0	1	1	0.310
Abdominal discomfort1	2	0	1	3	0.480
All2	15.3% (24/157)	32.3% (38/118)	30.3% (36/119)	98/394	0.002

¹Abdominal discomfort, but not of specified.

²The symptoms of a single adverse reaction are counted as 1, and a patient may have multiple adverse events.

P values were from two-side comparisons the differences among three treatment group. N: Total patient number; n: Patient number with side effects; 500 mg b.i.d.: Tetracycline twice daily; 750 mg b.i.d.: Tetracycline twice daily; 500 mg t.i.d.: Tetracycline three times daily.